-$1.02 EPS Expected for Myovant Sciences Ltd (MYOV) This Quarter

Wall Street brokerages predict that Myovant Sciences Ltd (NYSE:MYOV) will announce earnings of ($1.02) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Myovant Sciences’ earnings, with estimates ranging from ($1.05) to ($0.97). Myovant Sciences reported earnings per share of ($0.81) during the same quarter last year, which would suggest a negative year over year growth rate of 25.9%. The company is expected to announce its next earnings report on Thursday, June 6th.

On average, analysts expect that Myovant Sciences will report full year earnings of ($4.04) per share for the current fiscal year, with EPS estimates ranging from ($4.07) to ($4.00). For the next financial year, analysts forecast that the firm will post earnings of ($3.81) per share, with EPS estimates ranging from ($4.13) to ($3.50). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Myovant Sciences.

Myovant Sciences (NYSE:MYOV) last released its quarterly earnings data on Thursday, February 7th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.06).

Several analysts recently weighed in on MYOV shares. Evercore ISI started coverage on Myovant Sciences in a research note on Thursday, April 11th. They issued an “outperform” rating on the stock. Zacks Investment Research raised Myovant Sciences from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research note on Wednesday, April 3rd. JMP Securities reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Myovant Sciences in a research note on Monday, February 11th. Barclays upgraded Myovant Sciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $22.00 to $25.00 in a research report on Wednesday, February 13th. Finally, ValuEngine downgraded Myovant Sciences from a “buy” rating to a “hold” rating in a research report on Saturday. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $30.50.

Institutional investors have recently bought and sold shares of the business. RA Capital Management LLC raised its position in Myovant Sciences by 7.5% in the fourth quarter. RA Capital Management LLC now owns 3,711,549 shares of the company’s stock valued at $60,907,000 after purchasing an additional 259,690 shares during the last quarter. BB Biotech AG raised its position in Myovant Sciences by 0.8% in the fourth quarter. BB Biotech AG now owns 3,597,882 shares of the company’s stock valued at $59,041,000 after purchasing an additional 30,000 shares during the last quarter. Lord Abbett & CO. LLC raised its position in shares of Myovant Sciences by 0.9% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,913,548 shares of the company’s stock worth $31,401,000 after acquiring an additional 16,668 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Myovant Sciences by 3,012.4% during the fourth quarter. Bank of New York Mellon Corp now owns 369,320 shares of the company’s stock worth $6,060,000 after acquiring an additional 357,454 shares during the last quarter. Finally, First Manhattan Co. bought a new position in shares of Myovant Sciences during the fourth quarter worth about $292,000. Hedge funds and other institutional investors own 29.93% of the company’s stock.

NYSE:MYOV traded down $0.63 during trading hours on Wednesday, hitting $19.30. The company’s stock had a trading volume of 130,844 shares, compared to its average volume of 80,118. The firm has a market capitalization of $1.41 billion, a PE ratio of -8.01 and a beta of 0.79. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 2.08. Myovant Sciences has a twelve month low of $14.32 and a twelve month high of $27.45.

Myovant Sciences Company Profile

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading: Gross Domestic Product (GDP)

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.